Carregant...
YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)‐mutant resistance in vitro and in vivo
YL143 was identified as a novel wild‐type sparing EGFR(T790M) inhibitor with good pharmacokinetic properties. It potently suppresses EGFR(L858R/T790M) with an 50% inhibitory concentration (IC(50)) value of 2.0 ± 0.3 nmol/L, but is approximately 92‐folds less potent against EGFR(WT) kinase. YL143 sup...
Guardat en:
| Publicat a: | Cancer Med |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5911580/ https://ncbi.nlm.nih.gov/pubmed/29532998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1392 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|